DOT1L

Histone-lysine N-methyltransferase, H3 lysine-79 specific · Q8TEK3 · DOT1L on Sugi Atlas →

23,947 patent compounds predicted against DOT1L, 17,360 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
S-Adenosylhomocysteine (SCHEMBL8836)	1.00	9/20
S-Adenosylhomocysteine (SCHEMBL804238)	1.00	9/20
SCHEMBL571843	0.53	9/20
SCHEMBL571844	0.53	9/20
SCHEMBL571845	0.53	9/20
SCHEMBL95173	0.82	6/20
S-Adenosylhomocysteine (SCHEMBL753710)	0.78	6/20
SCHEMBL9754	0.62	6/20
SCHEMBL687554	0.53	6/20
Sinefungin (SCHEMBL167609)	1.00	5/20
Toyocamycin (SCHEMBL336095)	0.80	5/20
SCHEMBL505843	0.77	5/20
Ademetionine (SCHEMBL25177)	0.71	5/20
Ademetionine (SCHEMBL55479)	0.71	5/20
Ademetionine (SCHEMBL59293)	0.71	5/20
Ademetionine (SCHEMBL66767)	0.71	5/20
Ademetionine (SCHEMBL599664)	0.71	5/20
Ademetionine (SCHEMBL600368)	0.71	5/20
SCHEMBL536411	0.70	5/20
SCHEMBL952217	0.67	5/20

Clinical trials — most relevant to DOT1L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Tazemetostat and Palbociclib With CPX-351for R/R AML	PHASE1	RECRUITING
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma	PHASE1	RECRUITING
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment	PHASE1	ACTIVE_NOT_RECRUITING
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia	PHASE1	RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins	nan	COMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DOT1L binder may also engage these)

Protein	Name	Similarity
Q9TUG2	—	0.991	Q9TUG2 →
Q60698	—	0.990	Q60698 →
P12755	—	0.987	P12755 →
Q80U28	—	0.986	Q80U28 →
Q8WXG6	—	0.986	Q8WXG6 →
Q92622	—	0.986	Q92622 →
Q96SB3	—	0.985	Q96SB3 →
Q60611	—	0.985	Q60611 →
CBL	E3 ubiquitin-protein ligase CBL	0.985	landscape →
Q50H33	—	0.985	Q50H33 →
NCOR2	Nuclear receptor corepressor 2	0.984	landscape →
Q98TY6	—	0.984	Q98TY6 →
Q9UPW6	—	0.983	Q9UPW6 →
Q8K4S7	—	0.983	Q8K4S7 →
Q01826	—	0.983	Q01826 →
O00287	—	0.983	O00287 →
Q9UQB3	—	0.982	Q9UQB3 →
BCR	Breakpoint cluster region protein	0.982	landscape →
P49797	—	0.981	P49797 →
Q9UPT6	—	0.981	Q9UPT6 →
Q99LB0	—	0.981	Q99LB0 →
Q8N228	—	0.981	Q8N228 →
Q6PAJ1	—	0.980	Q6PAJ1 →
O35274	—	0.980	O35274 →
B3KU38	—	0.980	B3KU38 →
Q8VI24	—	0.980	Q8VI24 →
Q6R891	—	0.980	Q6R891 →
Q9Y2G1	—	0.980	Q9Y2G1 →
Q6NS60	—	0.980	Q6NS60 →
Q3UR85	—	0.980	Q3UR85 →